Patent US4263244A successfully refreshed from Google Patents.
Patent US4077949A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4077949A Expired / Lapsed US ⏱️ 0.0 years remaining

Polypeptide hormones of the thymus

Assignee: Memorial Sloan Kettering Cancer Center
•
Filing: 1975-08-22
•
Granted: 1978-03-07
•
Expires: 1995-08-22
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract There are disclosed closely related new polypeptides isolated from bovine thymus, which are distinct polypeptides denoted as Thymin I and Thymin II or Thymopoietin I and Thymopoietin II, respectively. Thymin I may be characterized as having a relative mobility (Rf) on 7% polyacrylamide gel disc electrophoresis of 0.63 with respect to methyl green at a pH of 4.3, and having the following structural sequence:

Inventors

  • 👤 Gideon Goldstein

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 03:30
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/66; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/854; Y10S930/00; Y10S930/01; Y10S930/18

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 77 words
A highly purified polypeptide named as Thymopoietin I and having the following amino acid sequence: H 2 n-gly-gln-phe-leu-glu-asp-pro-ser-val-leu-thr-lys-glu- lys-leu-lys-ser-glu-leu-val-ala-asn-asn-val-thr-leu-pro-ala-gly-glu- gln-arg-lys-asp-val-tyr-val-gln-leu-tyr-leu-gln-his-leu-thr-ala-val- lys-arg-cooh, said polypeptide existing in the physical form of a powder, said polypeptide having relative mobilities on 7% polyacrylamide disc electrophoresis of 0.3 at a pH of 8.9 with respect to bromophenol blue, and 0.63 at a pH of 4.3 with respect to methyl green, said polypeptide being therapeutically active at concentrations of 0.2-2 nanogram per ml.
Claim 2
Dependent Claim 77 words
A highly purified polypeptide named as Thymopoietin I and having the following amino acid sequence: H 2 n-gly-gln-phe-leu-glu-asp-pro-ser-val-leu-thr-lys-glu- lys-leu-lys-ser-glu-leu-val-ala-asn-asn-val-thr-leu-pro-ala-gly-glu- gln-arg-lys-asp-val-tyr-val-gln-leu-tyr-leu-gln-his-leu-thr-ala-val- lys-arg-cooh, said polypeptide existing in the physical form of a powder, said polypeptide having relative mobilities on 7% polyacrylamide disc electrophoresis of 0.3 at a pH of 8.9 with respect to bromophenol blue, and 0.63 at a pH of 4.3 with respect to methyl green, said polypeptide being therapeutically active at concentrations of 0.2-2 nanogram per ml.
Claim 3
Dependent Claim 77 words
A highly purified polypeptide named as Thymopoietin II and having the following amino acid sequence: H 2 n-ser-gln-phe-leu-glu-asp-pro-ser-val-leu-thr-lys-glu- lys-leu-lys-ser-glu-leu-val-ala-asn-asn-val-thr-leu-pro-ala-gly-glu- gln-arg-lys-asp-val-tyr-val-gln-leu-tyr-leu-gln-thr-leu-thr-ala-val- lys-arg-cooh, said polypeptide existing in the physical form of a powder, said polypeptide having relative mobilities on 7% polyacrylamide disc electrophoresis of 0.3 at a pH of 8.9 with respect to bromophenol blue, and 0.57 at a pH of 4.3 with respect to methyl green, said polypeptide being therapeutically active at concentrations of 0.2-2 nanogram per ml.
Claim 4
Dependent Claim 77 words
A highly purified polypeptide named as Thymopoietin II and having the following amino acid sequence: H 2 n-ser-gln-phe-leu-glu-asp-pro-ser-val-leu-thr-lys-glu- lys-leu-lys-ser-glu-leu-val-ala-asn-asn-val-thr-leu-pro-ala-gly-glu- gln-arg-lys-asp-val-tyr-val-gln-leu-tyr-leu-gln-thr-leu-thr-ala-val- lys-arg-cooh, said polypeptide existing in the physical form of a powder, said polypeptide having relative mobilities on 7% polyacrylamide disc electrophoresis of 0.3 at a pH of 8.9 with respect to bromophenol blue, and 0.57 at a pH of 4.3 with respect to methyl green, said polypeptide being therapeutically active at concentrations of 0.2-2 nanogram per ml.
Claim 5
Independent Claim 360 words
A method for the isolation from bovine thymus of the polypeptides Thymopoietin I and Thymopoietin II, which comprises homogenizing bovine thymus in buffered saline solution, heating to a temperature of about 60°-90° C. to complete homogenization, centrifuging and filtering to remove non-homogenized and insoluble materials and provide a resulting solution, subjecting this resulting solution to molecular sizing by contacting with a dialysate membrane of such size as to allow polypeptides to pass through the membrane while excluding materials having molecular weights above about 100,000, passing the resulting solution which passed through the membrane through a second dialysate membrane of such size so as to exclude materials having molecular weights below about 2,000, recovering therefrom a retentate containing materials having molecular weights of about 2,000-100,000 and of reduced volume, fractionating the resulting retentate by molecular exclusion chromatography at least two times by placing in a solution of ammonium bicarbonate and contacting the solution with a cross-linked dextran molecular sieve which totally excludes materials having molecular weights above about 30,000 wherein materials having molecular weights of less than about 1500 will totally permeable and recovering an extract containing materials having molecular weights in the range of about 4,000 to about 12,000, further fractionating the resulting extract by adsorption chromatography by dissolving the extract in a solution 0.001 M to 0.008 M phosphate buffer solution at a pH of about 6.8 and contacting with hydroxy apatite by passage through a column containing the hydroxyl apatite, and separation is effected by differential sticking on the hydroxyl apatite, the active fractions being retarded behind the void volume, collecting the active fractions by lyophilizing and desalting, fractionating to separate two active fractions by contact at least once by ion exchange chromatography by dissolving in a buffer base at a pH of about 10 to 11 and contacting with an anion exchanger comprising beads as the backbone with polymer groups attached thereon wherein the product is retained by the beads, recovering the product fractions by raising the molarity of the solution by linear concentration gradients, lyophilizing and desalting the resulting active fractions on a cross-linked dextran molecular sieve and recovering the purified Thymopoietin I and Thymopoietin II.
Claim 6
Independent Claim 360 words
A method for the isolation from bovine thymus of the polypeptides Thymopoietin I and Thymopoietin II, which comprises homogenizing bovine thymus in buffered saline solution, heating to a temperature of about 60°-90° C. to complete homogenization, centrifuging and filtering to remove non-homogenized and insoluble materials and provide a resulting solution, subjecting this resulting solution to molecular sizing by contacting with a dialysate membrane of such size as to allow polypeptides to pass through the membrane while excluding materials having molecular weights above about 100,000, passing the resulting solution which passed through the membrane through a second dialysate membrane of such size so as to exclude materials having molecular weights below about 2,000, recovering therefrom a retentate containing materials having molecular weights of about 2,000-100,000 and of reduced volume, fractionating the resulting retentate by molecular exclusion chromatography at least two times by placing in a solution of ammonium bicarbonate and contacting the solution with a cross-linked dextran molecular sieve which totally excludes materials having molecular weights above about 30,000 wherein materials having molecular weights of less than about 1500 will totally permeable and recovering an extract containing materials having molecular weights in the range of about 4,000 to about 12,000, further fractionating the resulting extract by adsorption chromatography by dissolving the extract in a solution 0.001 M to 0.008 M phosphate buffer solution at a pH of about 6.8 and contacting with hydroxy apatite by passage through a column containing the hydroxyl apatite, and separation is effected by differential sticking on the hydroxyl apatite, the active fractions being retarded behind the void volume, collecting the active fractions by lyophilizing and desalting, fractionating to separate two active fractions by contact at least once by ion exchange chromatography by dissolving in a buffer base at a pH of about 10 to 11 and contacting with an anion exchanger comprising beads as the backbone with polymer groups attached thereon wherein the product is retained by the beads, recovering the product fractions by raising the molarity of the solution by linear concentration gradients, lyophilizing and desalting the resulting active fractions on a cross-linked dextran molecular sieve and recovering the purified Thymopoietin I and Thymopoietin II.
Claim 7
Dependent Claim 24 words
A method according to claim 3 wherein the bovine thymus is homogenized in about 25% wet weight per volume of 0.1 M ammonium bicarbonate.
Claim 8
Dependent Claim 21 words
A method according to claim 4 wherein heating is carried out at a temperature of about 70° C. for 30 minutes.
Claim 9
Dependent Claim 24 words
A method according to claim 5 wherein the homogenized mixture is centrifuged after heating at 5,000 g for 30 minutes to remove non-homogenized materials.
Claim 10
Dependent Claim 28 words
A method according to claim 6 wherein the retentate from the second dialysis step is fractionated by molecular exclusion chromatography in a solution of 0.1 M ammonium bicarbonate.
Claim 11
Dependent Claim 51 words
A method according to claim 7 wherein the recovered materials from the second dialysis step are fractionated by ion exchange chromatography in the presence of an anion exchanger in 0.1 M ammonium bicarbonate and is later removed by raising the molarity of the solution to 0.8 M by linear concentration gradients.

References Cited (Backward Citations)

GB1195980A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-03-06 1981-09-05 1982-03-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-03-06 1985-09-05 1986-03-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-03-06 1989-09-05 1990-03-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag